SCHEMBL4146643

SCHEMBL4146643

NC(Cc1ccccc1)c1cncc(-c2ccc3[nH]c(=O)cc(O)c3c2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 3/20 0.43
BRD4 O60885 1/20 0.42
CDK2 P24941 7/20 0.41
CDK7 P50613 7/20 0.41
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
AKT1 P31749 6/20 0.40
DAPK3 O43293 2/20 0.39
RPS6KA5 O75582 2/20 0.39
RPS6KA4 O75676 2/20 0.39
PRKD3 O94806 2/20 0.39
MAP4K4 O95819 2/20 0.39
PAK4 O96013 2/20 0.39
CHEK2 O96017 2/20 0.39
PRKCG P05129 2/20 0.39
PIM1 P11309 2/20 0.39
PHKG2 P15735 2/20 0.39
PRKACA P17612 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL938434 0.83 ROCK2 (0.43) ROCK2BRD4CDK2CDK7KDM4E
SCHEMBL938433 0.83 ROCK2 (0.43) ROCK2BRD4CDK2CDK7KDM4E
SCHEMBL22191157 0.81 PDE3B (0.44) ROCK2CDK2CDK7PRMT5WDR77
SCHEMBL22191278 0.81 PDE3B (0.44) ROCK2CDK2CDK7PRMT5WDR77
SCHEMBL22191156 0.81 PDE3B (0.44) ROCK2CDK2CDK7PRMT5WDR77
SCHEMBL13554564 0.78 ROCK2 (0.48) ROCK2BRD4KDM4EALDH1A1ROCK1
SCHEMBL1753937 0.77 F11 (0.71) F11
SCHEMBL2105159 0.77 F11 (0.71) F11
SCHEMBL4158845 0.77 ROCK2 (0.41) ROCK2BRD4KDM4EALDH1A1PRKACA
SCHEMBL1196662 0.76 ROCK2 (0.48) ROCK2KDM4EALDH1A1ROCK1F11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181983-A1 SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL -MEYERS SQUIBB COMPANY 2009-07-16 US claimed
US-20090181983-A1 SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL -MEYERS SQUIBB COMPANY 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181983-A1 SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS TFPI, F11, F12 ROCK2 653/4885BRD4 2366/4885CDK2 577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.